Page 2459 - Williams Hematology ( PDFDrive )

2430 Index Index 2431

Etoposide (Cont.): Exosomes, platelet, 1848 gain of function mutations, 170
for acute lymphoblastic leukemia, 1515 Expressivity, 149 in mantle cell lymphoma, 170
for acute myelogenous leukemia, 1402t Extracellular matrix in myelodysplastic syndromes, 228t, 1346t,
in children, 1409 marrow, 61–64, 62t 1347, 1351
in older patients, 1408 vascular growth and, 2283–2284, 2284f in Ph-chromosome negative
adverse effects, 329, 1519t, 1520, 1534 Extracellular matrix glycoproteins, 266 myeloproliferative neoplasms, 229t
for α-heavy-chain disease, 1808 Extracellular matrix proteins (ECMs), 61–62 EZH2 (enhancer of zest homologue 2), 170
for Burkitt lymphoma, 1676 Extracellular signal-regulated kinase (ERK), EZH2 (enhancer of zest homologue 2)
for chronic lymphocytic leukemia, 1534 298, 1103 inhibitors, 337–338
for diffuse large B-cell lymphoma, 1628, Extracorporeal photochemotherapy/ Ezrin, 1006
1629t, 1630, 1631 photopheresis, 429t, 433, 1687
for enteropathy-associated T-cell Extramedullary blast crisis, 1465 F
lymphoma, 1700 Extramedullary disease, in myeloma, 1746 F1P1L1-PDGFR-α, 1279
for familial hemophagocytic Extramedullary hematopoiesis, 1323, 1324 F2, 1920, 1920f, 2135t
lymphohistiocytosis, 1228 Extramedullary marrow crisis, 1465–1466 F4/80 (EMR1), 1079–1080, 1081f, 1082
for hemophagocytic lymphohistiocytosis, Extramedullary tumors, 1285, 1324 F5, 1925, 1925f, 2135t, 2138
1115 Extranodal histiocytic sarcoma, 1110 F7, 1920, 1921f, 2135t, 2140
high-dose, 331t, 332t Extranodal lymphoma, 1502. See also F8 (FVIII), 1926, 1926f, 2114
for Hodgkin lymphoma, 1616 Primary extranodal lymphoma F8A, 2114
for myelodysplastic syndromes, 1362 Extranodal marginal zone lymphoma of F8B, 2114
for peripheral T-cell lymphoma, 1695– MALT type, 1663–1666 F9, 1921, 1921f
1696, 1697 chromosomal abnormalities F10, 1922, 1922f, 2135t, 2141–2142
resistance to, 319t gains, 1664t F11, 1929, 1929f, 2135t, 2143
secondary acute myelogenous leukemia losses, 1664t F13A, 2135t, 2144
and, 183, 1407 t(11;18), 184t, 224t, 1664, 1664t F13A1, 1935, 1935f, 2144
ETV6 (TEL), 228t, 230, 1346t, 1351 translocations, 184t, 187–188, 210, 224t, F13B, 2135t, 2144
ETV6-RUNX1, in acute lymphoblastic 1495t, 1577, 1664, 1664t FA/BRCA pathway, in Fanconi anemia, 527,
leukemia trisomy 3, 187–188 529f
acquired, 1507 clinical features, 1664–1665 F-actin, 481
detection, 1512 course and prognosis, 1666 Factitious anemia, 630
Down syndrome and, 1507 definition, 1663 Factitious purpura, 2107
features associated with, 1512, 1513t differential diagnosis, 1665 Factor II. See Prothrombin (factor II)
frequency, 1508t epidemiology, 1663 Factor V
immunologic classification and, 1512 etiology and pathogenesis, 1574, 1663– activated protein C and, 1954, 1955–1956
prognosis and, 183, 1513t, 1518, 1520– 1664 activation, 1924–1925, 1949, 1950
1521, 1521t gastric, 1581, 1664–1666, 1666f, 1666t antibodies, 2186
treatment response and, 1516 laboratory features, 1495t, 1595, 1595f, characteristics, 1916t, 1924, 2137
in utero development, 1508 1665, 1665f gene structure and variations, 1925, 1925f,
Evans syndrome staging, 1665 2138
course and prognosis, 840 therapy, 1665–1666 in platelets, 1845, 1856, 1924, 2137
laboratory features, 43, 832, 1804, 2002 Extranodal natural killer (NK)/T-cell structure, 1924, 1924f, 2137–2138
Evelyn-Malloy method, 792 lymphoma, nasal type, 1498t, Factor V deficiency (parahemophilia),
Everolimus 1500t, 1573, 1701–1702 2137–2139
adverse effects, 1796 Extraosseous plasmacytoma, 1497t clinical features, 2137
for mantle cell lymphoma, 1660t Extremities, 6, 9 definition and history, 2137
for Waldenström macroglobulinemia, Extrinsic pathway inhibitor. See Tissue factor gene mutations, 1925, 2135t, 2137
1795–1796 pathway inhibitor (TFPI) incidence, 2134t
Exchange transfusion Exudates, eye, 8 therapy, 2136t, 2138
for alloimmune hemolytic disease of the Eye disorders. See Ocular disorders Factor(s) V and VIII deficiency, 2134t, 2135t,
fetus and newborn, 856–857 Eye examination, 8 2136t, 2139–2140
for sickle cell disease, 776 EZH2 Factor V1, 1955
Excoriation, 8 in chronic myelomonocytic leukemia, Factor V2, 1955
Exercise-induced purpura, 2107 1468 Factor Va
Exercise tolerance, iron deficiency and, 631 in diffuse large B-cell lymphoma, 234t, activated protein C and, 1924–1925, 1955
Exfoliative dermatitis, 598 1626, 1627t platelet microparticles and, 1854
Exons, 147 in follicular lymphoma, 235t protein S and, 1949

Kaushansky_index_p2393-2506.indd 2430 9/21/15 3:21 PM